Loading...
The Ebola virus disease (EVD) outbreak that occurred in West Africa from 2013 to 2016 led the World Health Organization to develop plans to test experimental therapies for this highly lethal infection in future outbreaks. With the recognition of the EVD outbreak in the Democratic Republic of the Congo (DRC), an international team of investigators undertook the Pamoja Tulinde Maisha (PALM [“Together Save Lives”]) trial.
A total of 673 evaluable patients of any age with EVD confirmed by reverse-transcriptase polymerase chain reaction assay were enrolled an average of 5.5 days after symptom onset at one of four Ebola treatment centers in the DRC between November 2018 and August 2019. Patients were randomized 1:1:1:1 to receive REGN-EB3 (a mixtu…